QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Amin, Nadia Laila
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia? [electronic resource] - Archives of disease in childhood Mar 2016 - 287-90 p. digital
Publication Type: Journal Article; Review
1468-2044
10.1136/archdischild-2015-309934 doi
Adolescent
Alendronate--adverse effects
Antineoplastic Agents--therapeutic use
Bone Density Conservation Agents--adverse effects
Diphosphonates--adverse effects
Female
Humans
Osteonecrosis--chemically induced
Pain--drug therapy
Pamidronate
Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Risedronic Acid--adverse effects
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia? [electronic resource] - Archives of disease in childhood Mar 2016 - 287-90 p. digital
Publication Type: Journal Article; Review
1468-2044
10.1136/archdischild-2015-309934 doi
Adolescent
Alendronate--adverse effects
Antineoplastic Agents--therapeutic use
Bone Density Conservation Agents--adverse effects
Diphosphonates--adverse effects
Female
Humans
Osteonecrosis--chemically induced
Pain--drug therapy
Pamidronate
Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Risedronic Acid--adverse effects